Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 620 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 620 shares of the stock in a transaction on Monday, May 18th. The stock was sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares in the company, valued at approximately $3,278,948.54. This trade represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Trading Up 1.2%

EW opened at $82.39 on Tuesday. The firm’s fifty day moving average is $81.48 and its two-hundred day moving average is $82.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The firm has a market cap of $47.44 billion, a PE ratio of 43.82, a price-to-earnings-growth ratio of 2.04 and a beta of 0.87. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Finally, Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $95.65.

Institutional Trading of Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the 3rd quarter worth about $25,000. Finally, Hilton Head Capital Partners LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $28,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.